Kamada Ltd. logo
Kamada Ltd. KMDA
$ 6.95 -1.56%

Annual report 2024
added 10-25-2025

report update icon

Kamada Ltd. Deferred Revenue 2011-2025 | KMDA

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Kamada Ltd.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - 222 K 589 K 461 K 4.93 M 4.9 M 1.92 M 2.92 M 5.45 M 8.18 M 7.27 M
202420242023202320222022202120212020202020192019201820182017201720162016201520152014201420132013201220122011201110 M10 M8 M8 M6 M6 M4 M4 M2 M2 M00
Download SVG
Download PNG
Download CSV

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
8.18 M 222 K 3.68 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
AgeX Therapeutics AgeX Therapeutics
AGE
283 K $ 11.3 -10.17 % $ 12.2 K -
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
3.68 M $ 4.37 -1.58 % $ 28.1 M chinaChina
Axon Enterprise Axon Enterprise
AXON
613 M $ 755.0 0.8 % $ 57.2 B usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
5.1 M $ 0.43 -16.75 % $ 25.8 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
1.11 M $ 0.27 -29.58 % $ 126 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
187 M $ 184.71 0.49 % $ 251 B cayman-islandsCayman-islands
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
959 K $ 4.93 1.02 % $ 90.8 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
1.3 M $ 0.29 -18.52 % $ 27.3 M britainBritain
Advaxis Advaxis
ADXS
165 K $ 0.31 -9.65 % $ 45.9 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
604 K $ 3.93 -5.76 % $ 99.8 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
2.85 M $ 6.2 - $ 154 M usaUSA
Zymeworks Zymeworks
ZYME
32.9 M $ 6.42 - $ 404 M canadaCanada
Aeterna Zentaris Aeterna Zentaris
AEZS
2.19 M $ 5.72 5.93 % $ 314 M canadaCanada
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
4.4 M $ 9.5 - $ 1.7 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
1.72 M $ 2.58 -4.8 % $ 255 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
19.5 M $ 16.73 0.12 % $ 10.9 B australiaAustralia
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
26 K $ 0.56 7.23 % $ 2.72 M usaUSA
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
541 K $ 179.68 - $ 10.9 B usaUSA
Moderna Moderna
MRNA
153 M $ 25.35 -4.91 % $ 9.73 B usaUSA
Merus N.V. Merus N.V.
MRUS
29.9 M $ 94.9 0.32 % $ 6.09 B niderlandNiderland
Kaleido Biosciences Kaleido Biosciences
KLDO
498 K $ 0.29 -3.69 % $ 12.4 M usaUSA
Humanigen Humanigen
HGEN
883 K $ 0.04 -81.12 % $ 4.28 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
6.3 M $ 0.39 - $ 26.5 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
2.21 M $ 0.47 - $ 12.5 M belgiumBelgium
Nektar Therapeutics Nektar Therapeutics
NKTR
5.52 M $ 60.92 -2.64 % $ 11.6 B usaUSA
Brickell Biotech Brickell Biotech
BBI
1.8 M $ 2.11 -5.38 % $ 6.06 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
1.7 M $ 0.05 -15.0 % $ 3.04 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
13 M $ 0.06 -55.98 % $ 2.15 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
2.75 M $ 8.37 - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
240 K $ 3.17 1.93 % $ 17.4 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
1.55 M $ 0.37 -10.95 % $ 876 K usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
128 K $ 11.53 -0.17 % $ 1.82 B usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
1.24 M $ 20.01 - $ 958 M usaUSA
Oragenics Oragenics
OGEN
14.2 K $ 1.29 -2.27 % $ 2.9 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
1.11 M $ 49.55 -6.81 % $ 3.04 B usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
927 K $ 1.22 0.83 % $ 115 M canadaCanada